Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer

BACKGROUND: Metastatic colorectal cancers (MCRCs) with microsatellite stability (MSS) are resistant to immunotherapy with programmed cell death protein 1 (PD‐1) and programmed death‐ligand 1 inhibitors. However, the addition of regorafenib to nivolumab was recently associated with a high response ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chongkai, Chevalier, Dawnyel, Saluja, Janelle, Sandhu, Jaideep, Lau, Cecilia, Fakih, Marwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Gastrointestinal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418365/
https://www.ncbi.nlm.nih.gov/pubmed/32406541
http://dx.doi.org/10.1634/theoncologist.2020-0161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418365/
https://www.ncbi.nlm.nih.gov/pubmed/32406541
http://dx.doi.org/10.1634/theoncologist.2020-0161

Ejemplares similares